Thus, miR-138 is a tumor suppressor through the BCR-ABL/GATA1/miR-138 network, indicating CML pathogenesis and its clinical response to Imatinib.   52. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.